Severity: Warning
Message: file_get_contents(https://...@pubfacts.com&api_key=b8daa3ad693db53b1410957c26c9a51b4908&a=1): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
Filename: helpers/my_audit_helper.php
Line Number: 176
Backtrace:
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 176
Function: file_get_contents
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 250
Function: simplexml_load_file_from_url
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 3122
Function: getPubMedXML
File: /var/www/html/application/controllers/Detail.php
Line: 575
Function: pubMedSearch_Global
File: /var/www/html/application/controllers/Detail.php
Line: 489
Function: pubMedGetRelatedKeyword
File: /var/www/html/index.php
Line: 316
Function: require_once
Osteosarcoma is a primary malignant bone tumor, which affects children, adolescents, and young adults commonly. MicroRNAs (miRNAs) have been proved to be dysregulated in different cancers, including osteosarcoma. Although miR-320a has been implicated in many types of malignancies, little is known about the role of miR-320a in osteosarcoma. In this study, we show that the overexpression of miR-320a or knockdown of cytoplasmic polyadenylation element-binding protein 1 (CPEB1) inhibited osteosarcoma cell migration and invasion. miR-320a downregulates CPEB1 expression by directly targeting the CPEB1 3'-UTR. Furthermore, CPEB1 reintroduction reversed the antiproliferation, antimigration, and antiinvasion roles of miR-320a, indicating that miR-320a might function as a tumor suppressor in osteosarcoma through CPEB1. In conclusion, our study demonstrates that miR-320a plays a critical role in osteosarcoma progression and may provide a potential therapeutic target for osteosarcoma.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7163091 | PMC |
http://dx.doi.org/10.1002/cam4.2919 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!